最新ニュース Medtronic (NYSE:MDT) 株価情報

Medtronic

One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.

Medtronic PLC

Measurable Data Token - United States Dollar

MEDIA TECHS INC by Media Technologies Inc.

Media Technologies Inc

MEDIA TEK INC by Media Tek Inc.

MANDATUM OYJ U/ADR by MANDATUM OYJ

MediaTek Inc

MEDITERRANEAN TOWERS LTD by Mediterranean Towers LTD

Mediterranean Towers Ltd

Disclosed in a recent SEC filing on January 28, Martha, Chairman and CEO at Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), made a noteworthy transaction involving the exercise of company stock options.
What Happened: Disclosed in a Form 4 filing on Tuesday with the <a href="https://www.sec.gov/Archives/edgar/data/0001613103/000161310325000014//Archives/edgar/data/1613103/000161310325000014/0001613103-25-000014-index.htm">U.S. Securities and Exchange Commission</a>, Martha, Chairman and CEO at Medtronic, executed a strategic derivative sale. This involved exercising stock options for 34,741 shares of MDT, resulting in a transaction value of $618,563.
Currently, Medtronic shares are trading up 0.72%, priced at $92.64 during Wednesday's morning. This values Martha's 34,741 shares at $618,563.
<h3>All You Need to Know About Medtronic</h3>
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.
<h3>Medtronic: A Financial Overview</h3>
Revenue Growth: Medtronic's remarkable performance in 3 months is evident. As of 31 October, 2024, the company achieved an impressive revenue growth rate of 5.25%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Analyzing Profitability Metrics:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 64.94%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Medtronic's EPS reflects a decline, falling below the industry average with a current EPS of 0.99.
</li>
</ul>
Debt Management: Medtronic's debt-to-equity ratio is below the industry average. With a ratio of 0.58, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Navigating Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 28.13, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 3.65 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio lower than industry benchmarks at 16.15, Medtronic presents an attractive value opportunity.
</li>
</ul>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Uncovering the Importance of Insider Activity</h3>
Insightful as they may be, insider transactions should be considered alongside a thorough examination of other investment criteria.
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>Unlocking the Meaning of Transaction Codes</h3>
Surveying the realm of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often give prominence to those unfolding in the open market, systematically detailed in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001613103">Check Out The Full List Of Medtronic's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Insider Trades

Trading Ideas

Insider Activity Update: Geoffrey Martha Executes Options Exercise, Resulting In $618K At Medtronic

Matthew Walter, SVP at Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), reported a large exercise of company stock options on January 28, according to a new SEC filing.
What Happened: The latest Form 4 filing on Tuesday with the <a href="https://www.sec.gov/Archives/edgar/data/0001613103/000161310325000016//Archives/edgar/data/1613103/000161310325000016/0001613103-25-000016-index.htm">U.S. Securities and Exchange Commission</a> uncovered Walter, SVP at Medtronic, exercising stock options for 1,337 shares of MDT. The total transaction was valued at $23,805.
Currently, Medtronic shares are trading up 0.72%, priced at $92.64 during Wednesday's morning. This values Walter's 1,337 shares at $23,805.
<h3>All You Need to Know About Medtronic</h3>
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.
<h3>Understanding the Numbers: Medtronic's Finances</h3>
Revenue Growth: Medtronic displayed positive results in 3 months. As of 31 October, 2024, the company achieved a solid revenue growth rate of approximately 5.25%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Navigating Financial Profits:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 64.94%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Medtronic's EPS reflects a decline, falling below the industry average with a current EPS of 0.99.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.58, Medtronic adopts a prudent financial strategy, indicating a balanced approach to debt management.
Valuation Metrics: A Closer Look
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 28.13, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: The P/S ratio of 3.65 is lower than the industry average, implying a discounted valuation for Medtronic's stock in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): At 16.15, Medtronic's EV/EBITDA ratio reflects a below-par valuation compared to industry averages signalling undervaluation
</li>
</ul>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Relevance of Insider Transactions</h3>
Insider transactions, although significant, should be considered within the larger context of market analysis and trends.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Deciphering Transaction Codes in Insider Filings</h3>
Surveying the realm of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often give prominence to those unfolding in the open market, systematically detailed in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001613103">Check Out The Full List Of Medtronic's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Update: Matthew Walter Engages In Options Exercise At Medtronic Realizing $23K

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LXRX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$1.00</td>
<td>$168.9K</td>
<td>10.7K</td>
<td>17.1K</td>
</tr>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$93.00</td>
<td>$49.9K</td>
<td>25</td>
<td>604</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$130.00</td>
<td>$42.9K</td>
<td>6.5K</td>
<td>520</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$57.50</td>
<td>$53.5K</td>
<td>1.9K</td>
<td>112</td>
</tr>
<tr>
<td>AKRO</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$30.00</td>
<td>$102.8K</td>
<td>436</td>
<td>56</td>
</tr>
<tr>
<td>LNTH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$100.00</td>
<td>$45.0K</td>
<td>124</td>
<td>47</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$650.00</td>
<td>$60.4K</td>
<td>70</td>
<td>30</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$720.00</td>
<td>$65.7K</td>
<td>6</td>
<td>25</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$540.00</td>
<td>$27.6K</td>
<td>625</td>
<td>21</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding LXRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>), we observe a call option sweep with bearish sentiment. It expires in 24 day(s) on February 21, 2025. Parties traded 11262 contract(s) at a $1.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $168.9K, with a price of $15.0 per contract. There were 10734 open contracts at this strike prior to today, and today 17155 contract(s) were bought and sold. 
• For MDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), we notice a call option sweep that happens to be bearish, expiring in 24 day(s) on February 21, 2025. This event was a transfer of 316 contract(s) at a $93.00 strike. This particular call needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $49.9K, with a price of $158.0 per contract. There were 25 open contracts at this strike prior to today, and today 604 contract(s) were bought and sold. 
• Regarding ABT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), we observe a call option sweep with bearish sentiment. It expires in 24 day(s) on February 21, 2025. Parties traded 272 contract(s) at a $130.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $42.9K, with a price of $158.0 per contract. There were 6570 open contracts at this strike prior to today, and today 520 contract(s) were bought and sold. 
• Regarding CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we observe a call option sweep with bullish sentiment. It expires in 143 day(s) on June 20, 2025. Parties traded 100 contract(s) at a $57.50 strike. This particular call needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $53.5K, with a price of $535.0 per contract. There were 1923 open contracts at this strike prior to today, and today 112 contract(s) were bought and sold. 
• Regarding AKRO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKRO#NASDAQ">AKRO</a>), we observe a call option trade with neutral sentiment. It expires in 24 day(s) on February 21, 2025. Parties traded 46 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $102.8K, with a price of $2235.0 per contract. There were 436 open contracts at this strike prior to today, and today 56 contract(s) were bought and sold. 
• For LNTH (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>), we notice a call option sweep that happens to be bullish, expiring in 143 day(s) on June 20, 2025. This event was a transfer of 47 contract(s) at a $100.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $45.0K, with a price of $968.0 per contract. There were 124 open contracts at this strike prior to today, and today 47 contract(s) were bought and sold. 
• Regarding TMO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), we observe a call option trade with bearish sentiment. It expires in 234 day(s) on September 19, 2025. Parties traded 30 contract(s) at a $650.00 strike. The total cost received by the writing party (or parties) was $60.4K, with a price of $2016.0 per contract. There were 70 open contracts at this strike prior to today, and today 30 contract(s) were bought and sold. 
• Regarding REGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>), we observe a call option trade with bullish sentiment. It expires in 52 day(s) on March 21, 2025. Parties traded 25 contract(s) at a $720.00 strike. The total cost received by the writing party (or parties) was $65.7K, with a price of $2630.0 per contract. There were 6 open contracts at this strike prior to today, and today 25 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a call option trade that happens to be bullish, expiring in 79 day(s) on April 17, 2025. This event was a transfer of 10 contract(s) at a $540.00 strike. The total cost received by the writing party (or parties) was $27.6K, with a price of $2760.0 per contract. There were 625 open contracts at this strike prior to today, and today 21 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

AKRO

LNTH

LXRX

REGN

9 Health Care Stocks With Whale Alerts In Today's Session

Medtronic plc (NYSE:&nbsp;MDT), a global leader in healthcare technology,&nbsp;today announced that Thierry Piéton has been appointed Chief Financial Officer for the company, effective March 3, 2025. He will report to Medtronic Chairman and Chief Executive Officer Geoff Martha and will join the Medtronic Executive Committee. Piéton joins Medtronic from Renault Group, where he has served as Chief Financial Officer since March 2022. Gary Corona, who has been serving as interim CFO, will continue in this role until Piéton joins Medtronic, after which Corona will become Senior Vice President, Corporate Finance and will remain on the Medtronic Executive Committee.

Medtronic Names Thierry Piéton As New CFO, Effective March 2025

WIIM

Medtronic shares are trading higher after the company announced that the Centers for Medicare & Medicaid Services is opening a national coverage analysis for Symplicity Spyral Renal Denervation System.

National coverage analysis is the first-of-its kind for a minimally invasive, interventional treatment for high blood pressure
<ul>
<li>Milestone is supported by large public health need and robust, long-term data from the SPYRAL-HTN global clinical program</li>
</ul>
GALWAY, Ireland, Jan. 13, 2025 /PRNewswire/ -- Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), a global leader in healthcare technology, today announced&nbsp;that the Centers for Medicare &amp; Medicaid Services (CMS) is opening a national coverage analysis (NCA) on renal denervation, a process that will allow the agency to review and develop a national Medicare coverage policy for renal denervation procedures for patients with hypertension. This national coverage analysis was initiated by CMS in response to Medtronic&#39;s request to support Medicare beneficiary access to the Symplicity&trade; Spyral renal denervation (RDN) system, used in the Symplicity blood pressure procedure.

Biotech

General

Medtronic Receives CMS National Coverage Analysis For Symplicity Spyral Renal Denervation System; Expected Completion Date For National Coverage Analysis Is Oct 11

Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), a global leader in healthcare technology, announced today CE (Conformité Européenne) Mark approval in the European Union (EU) and the United Kingdom (UK) for BrainSense&#x2122; Adaptive deep brain stimulation (aDBS) and BrainSense&#x2122; Electrode Identifier (EI), having achieved the standards required by the EU Medical Device Regulation (MDR). In addition, the first programming was completed today, performed by Martijn Beudel, MD, PhD, neurologist and associate professor, Department of Neurology, Amsterdam University Medical Center. This landmark approval and first-in-Europe patient programming demonstrate significant advancements in personalized DBS therapy for people with Parkinson's in Europe, including the UK.

Government

Regulations

Medtronic Gains CE Mark Approval for BrainSense Adaptive DBS, Advancing Parkinson's Treatment in Europe and UK

Barclays analyst Matt Miksic initiated coverage on Anteris Technologies Global Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVR#NASDAQ">AVR</a>) with a <a href="https://www.benzinga.com/quote/AVR/analyst-ratings" target="_blank" rel="noreferrer noopener">Positive rating and a forecast of $22</a>.
The analyst notes that Anteris Technologies&#8217; DurAVR valve system is expected to become the second balloon-expandable transcatheter valve replacement (BEV TAVR) system by 2028
Clinicians show a clear preference for BEV TAVR systems over self-expanding (SEV) systems from Medtronic plc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) and Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>).
The analyst points out that DurAVR, positioned as an emerging next-gen TAVR player, is on track to capture 4%-5% of the U.S. TAVR market by 2030.
Despite strong data from MDT in 2024, clinicians still favor balloon-expandable (BEV) TAVR systems, of which DurAVR is set to be the second.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/42851889/meta-ditches-fact-checking-for-community-notes-zuckerberg-says-opportunity-to-restore-free-expression" rel="noreferrer noopener">Meta Drops Fact-Checking For Community Notes: Zuckerberg Sees &#8216;Opportunity To Restore Free Expression&#8217;</a>
The analyst estimates that in the U.S., around 130,000 isolated aortic valve replacement (AVR) procedures are performed annually, out of about 550,000 patients with symptomatic severe aortic stenosis (ssAS). Additionally, 175,000 new ssAS patients are diagnosed each year, while 100,000 patients die annually due to lack of treatment.
Although TAVR market growth has slowed, the analyst sees the market as underpenetrated and views it as a promising target for the next-gen DurAVR platform.
In addition to its BEV delivery system, DurAVR offers superior hemodynamics and laminar blood flow, combining the best features of leading TAVR platforms for more favorable hemodynamics and a low-profile valve height.
Early clinical evidence suggests that DurAVR could outperform other leading TAVR platforms in areas such as hemodynamics, outcomes in valve-in-valve (VIV) procedures and potentially in long-term durability, thanks to the company&#8217;s proprietary ADAPT tissue technology, Miksic writes.
For FY25, the analyst estimates the company to report a loss of $(1.30) per share.
Price Action: AVR shares are trading higher by 2.67% to $5.760&nbsp;at last check Tuesday.
Read now:
<ul>
<li><a href="https://www.benzinga.com/25/01/42830046/amd-reveals-new-ai-processors-gaming-products-ahead-of-ces-2025-shares-rise" target="_blank" rel="noreferrer noopener">AMD Unveils ‘Next Generation' AI Processors, Gaming Gear Ahead Of CES 2025</a></li>
</ul>
Anteris logo courtesy of company

Equities

Markets

Movers

Anteris Technologies Positioned To Capture 4%-5% Of US Transcatheter Valve Replacement Market By 2030: Analyst

<a href="https://news.medtronic.com/2025-01-06-Medtronic-receives-CE-Mark-for-leading-transcatheter-pulmonary-valve-replacement-system-for-congenital-heart-disease" title="https://news.medtronic.com/2025-01-06-Medtronic-receives-CE-Mark-for-leading-transcatheter-pulmonary-valve-replacement-system-for-congenital-heart-disease">https://news.medtronic.com/2025-01-06-Medtronic-receives-CE-Mark-for-leading-transcatheter-pulmonary-valve-replacement-system-for-congenital-heart-disease</a>
&nbsp;
Harmony&#x2122; Transcatheter Pulmonary Valve system approval expands minimally invasive treatment options for patients with congenital heart disease across European Union
Medtronic plc, a global leader in healthcare technology, today announced it received CE (Conformité Européenne) Mark for the Harmony&#x2122; Transcatheter Pulmonary Valve (TPV) System, a minimally invasive alternative to open-heart surgery for congenital heart disease patients with native or surgically repaired right ventricular outflow tract (RVOT). The Harmony TPV system has already been implanted in over 2,200 patients and now has access to help many more patients across the European Union.
The Harmony TPV system is designed to treat patients with RVOT anomalies with severe pulmonary valve regurgitation (PR), a condition where blood leaks back into the right lower chamber of the heart after being pumped into the lungs. Harmony TPV system clinical trials demonstrate ease of implant, conformability to the anatomy, and strong clinical and hemodynamic outcomes for congenital heart disease patients up to three years.

Global

Medtronic Receives CE Mark For Leading Transcatheter Pulmonary Valve Replacement System For Congenital Heart Disease

Medtronic's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) short percent of float has fallen 16.13% since its last report. The company recently reported that it has 10.01 million shares sold short, which is 0.78% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.35 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Medtronic Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735068618_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Medtronic has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Medtronic's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Medtronic's peer group average for short interest as a percentage of float is 3.63%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Medtronic's Recent Short Interest

Truist Securities analyst Richard Newitter maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Hold and lowers the price target from $93 to $89.

Price Target

Analyst Ratings

Truist Securities Maintains Hold on Medtronic, Lowers Price Target to $89

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$15.00</td>
<td>$28.7K</td>
<td>19.8K</td>
<td>1.3K</td>
</tr>
<tr>
<td>CADL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$6.00</td>
<td>$44.6K</td>
<td>1.2K</td>
<td>995</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$25.00</td>
<td>$28.7K</td>
<td>27.4K</td>
<td>566</td>
</tr>
<tr>
<td>MDT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$75.00</td>
<td>$70.6K</td>
<td>95</td>
<td>286</td>
</tr>
<tr>
<td>RXRX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$10.00</td>
<td>$35.2K</td>
<td>5.8K</td>
<td>273</td>
</tr>
<tr>
<td>AMED</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$90.00</td>
<td>$147.5K</td>
<td>6.3K</td>
<td>250</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$580.00</td>
<td>$37.6K</td>
<td>1.0K</td>
<td>148</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/13/24</td>
<td>$55.00</td>
<td>$26.5K</td>
<td>1.0K</td>
<td>130</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$270.00</td>
<td>$123.5K</td>
<td>217</td>
<td>48</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/24/25</td>
<td>$105.00</td>
<td>$34.0K</td>
<td>32</td>
<td>32</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding TEVA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), we observe a call option sweep with bearish sentiment. It expires in 37 day(s) on January 17, 2025. Parties traded 100 contract(s) at a $15.00 strike. This particular call needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $28.7K, with a price of $287.0 per contract. There were 19843 open contracts at this strike prior to today, and today 1350 contract(s) were bought and sold. 
• Regarding CADL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>), we observe a call option sweep with bearish sentiment. It expires in 9 day(s) on December 20, 2024. Parties traded 372 contract(s) at a $6.00 strike. This particular call needed to be split into 22 different trades to become filled. The total cost received by the writing party (or parties) was $44.6K, with a price of $120.0 per contract. There were 1230 open contracts at this strike prior to today, and today 995 contract(s) were bought and sold. 
• For PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we notice a call option sweep that happens to be bullish, expiring in 401 day(s) on January 16, 2026. This event was a transfer of 101 contract(s) at a $25.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $28.7K, with a price of $285.0 per contract. There were 27415 open contracts at this strike prior to today, and today 566 contract(s) were bought and sold. 
• For MDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), we notice a put option sweep that happens to be bearish, expiring in 282 day(s) on September 19, 2025. This event was a transfer of 286 contract(s) at a $75.00 strike. This particular put needed to be split into 34 different trades to become filled. The total cost received by the writing party (or parties) was $70.6K, with a price of $247.0 per contract. There were 95 open contracts at this strike prior to today, and today 286 contract(s) were bought and sold. 
• Regarding RXRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>), we observe a call option trade with neutral sentiment. It expires in 401 day(s) on January 16, 2026. Parties traded 150 contract(s) at a $10.00 strike. The total cost received by the writing party (or parties) was $35.2K, with a price of $235.0 per contract. There were 5818 open contracts at this strike prior to today, and today 273 contract(s) were bought and sold. 
• Regarding AMED (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>), we observe a put option trade with bearish sentiment. It expires in 37 day(s) on January 17, 2025. Parties traded 250 contract(s) at a $90.00 strike. The total cost received by the writing party (or parties) was $147.5K, with a price of $590.0 per contract. There were 6378 open contracts at this strike prior to today, and today 250 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a put option sweep that happens to be bullish, expiring in 37 day(s) on January 17, 2025. This event was a transfer of 8 contract(s) at a $580.00 strike. This particular put needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $37.6K, with a price of $4710.0 per contract. There were 1038 open contracts at this strike prior to today, and today 148 contract(s) were bought and sold. 
• For CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we notice a put option sweep that happens to be bearish, expiring in 2 day(s) on December 13, 2024. This event was a transfer of 100 contract(s) at a $55.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $26.5K, with a price of $265.0 per contract. There were 1033 open contracts at this strike prior to today, and today 130 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a put option sweep with bearish sentiment. It expires in 401 day(s) on January 16, 2026. Parties traded 47 contract(s) at a $270.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $123.5K, with a price of $2630.0 per contract. There were 217 open contracts at this strike prior to today, and today 48 contract(s) were bought and sold. 
• Regarding NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we observe a call option trade with bullish sentiment. It expires in 44 day(s) on January 24, 2025. Parties traded 32 contract(s) at a $105.00 strike. The total cost received by the writing party (or parties) was $34.0K, with a price of $1065.0 per contract. There were 32 open contracts at this strike prior to today, and today 32 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMED

AMGN

CADL

RXRX

TEVA

10 Health Care Stocks Whale Activity In Today's Session

Looking into the current session, Medtronic Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) shares are trading at $85.62, after a 1.06% decrease. Over the past month, the stock fell by 4.53%, but over the past year, it actually increased by 8.32%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2024/1733257847_0.png" alt="Past Year Chart" />

<h3>A Look at Medtronic P/E Relative to Its Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 69.67 in the Health Care Equipment &amp; Supplies industry, Medtronic Inc. has a lower P/E ratio of 26.46. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1733257847_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Price Over Earnings Overview: Medtronic

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/06/24</td>
<td>$86.00</td>
<td>$29.5K</td>
<td>72</td>
<td align="right">680</td>
</tr>
<tr>
<td>GEHC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/06/24</td>
<td>$84.00</td>
<td>$41.1K</td>
<td>24</td>
<td align="right">368</td>
</tr>
<tr>
<td>IBRX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$4.50</td>
<td>$25.0K</td>
<td>635</td>
<td align="right">330</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$720.00</td>
<td>$227.0K</td>
<td>99</td>
<td align="right">293</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$26.00</td>
<td>$94.8K</td>
<td>2.4K</td>
<td align="right">168</td>
</tr>
<tr>
<td>BSX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$75.00</td>
<td>$259.5K</td>
<td>533</td>
<td align="right">150</td>
</tr>
<tr>
<td>APLT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.00</td>
<td>$33.0K</td>
<td>6.4K</td>
<td align="right">135</td>
</tr>
<tr>
<td>HROW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$50.00</td>
<td>$31.9K</td>
<td>776</td>
<td align="right">118</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$240.00</td>
<td>$55.0K</td>
<td>491</td>
<td align="right">114</td>
</tr>
<tr>
<td>PSTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$5.00</td>
<td>$44.2K</td>
<td>85</td>
<td align="right">110</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding MDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), we observe a put option sweep with bearish sentiment. It expires in 7 day(s) on December 6, 2024. Parties traded 674 contract(s) at a $86.00 strike. This particular put needed to be split into 44 different trades to become filled. The total cost received by the writing party (or parties) was $29.5K, with a price of $44.0 per contract. There were 72 open contracts at this strike prior to today, and today 680 contract(s) were bought and sold. 
• Regarding GEHC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>), we observe a put option sweep with neutral sentiment. It expires in 7 day(s) on December 6, 2024. Parties traded 360 contract(s) at a $84.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $41.1K, with a price of $113.0 per contract. There were 24 open contracts at this strike prior to today, and today 368 contract(s) were bought and sold. 
• Regarding IBRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>), we observe a put option sweep with neutral sentiment. It expires in 168 day(s) on May 16, 2025. Parties traded 260 contract(s) at a $4.50 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $25.0K, with a price of $95.0 per contract. There were 635 open contracts at this strike prior to today, and today 330 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a put option trade with bullish sentiment. It expires in 112 day(s) on March 21, 2025. Parties traded 100 contract(s) at a $720.00 strike. The total cost received by the writing party (or parties) was $227.0K, with a price of $2270.0 per contract. There were 99 open contracts at this strike prior to today, and today 293 contract(s) were bought and sold. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a call option sweep that happens to be bearish, is expiring today. Parties traded 158 contract(s) at a $26.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $94.8K, with a price of $600.0 per contract. There were 2480 open contracts at this strike prior to today, and today 168 contract(s) were bought and sold. 
• Regarding BSX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>), we observe a call option sweep with bullish sentiment. It expires in 84 day(s) on February 21, 2025. Parties traded 150 contract(s) at a $75.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $259.5K, with a price of $1730.0 per contract. There were 533 open contracts at this strike prior to today, and today 150 contract(s) were bought and sold. 
• Regarding APLT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLT#NASDAQ">APLT</a>), we observe a put option trade with bearish sentiment. It expires in 49 day(s) on January 17, 2025. Parties traded 110 contract(s) at a $5.00 strike. The total cost received by the writing party (or parties) was $33.0K, with a price of $300.0 per contract. There were 6422 open contracts at this strike prior to today, and today 135 contract(s) were bought and sold. 
• For HROW (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>), we notice a put option sweep that happens to be bullish, expiring in 413 day(s) on January 16, 2026. This event was a transfer of 19 contract(s) at a $50.00 strike. This particular put needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $31.9K, with a price of $1680.0 per contract. There were 776 open contracts at this strike prior to today, and today 118 contract(s) were bought and sold. 
• For DHR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), we notice a call option trade that happens to be bearish, expiring in 21 day(s) on December 20, 2024. This event was a transfer of 110 contract(s) at a $240.00 strike. The total cost received by the writing party (or parties) was $55.0K, with a price of $500.0 per contract. There were 491 open contracts at this strike prior to today, and today 114 contract(s) were bought and sold. 
• For PSTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>), we notice a call option trade that happens to be bullish, expiring in 49 day(s) on January 17, 2025. This event was a transfer of 100 contract(s) at a $5.00 strike. The total cost received by the writing party (or parties) was $44.2K, with a price of $442.0 per contract. There were 85 open contracts at this strike prior to today, and today 110 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APLT

GEHC

Hims & Hers Health, Inc. Class A Common Stock

HIMS

HROW

IBRX

PSTX

10 Health Care Stocks With Whale Alerts In Today's Session

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Stifel raised the price target for Semtech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) from $58 to $65. Stifel analyst Tore Svanberg maintained a Buy rating. Semtech shares closed at $53.44 on Monday. <a href="https://www.benzinga.com/quote/SMTC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities raised the price target for Woodward, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) from $187 to $226. Truist Securities analyst Michael Ciarmoli reiterated a Buy rating. Woodward shares closed at $179.29 on Monday. <a href="https://www.benzinga.com/quote/WWD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays boosted Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) price target from $105 to $109. Barclays analyst Matt Miksic maintained an Overweight rating. Medtronic shares settled at $85.75 on Monday. <a href="https://www.benzinga.com/quote/MDT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo boosted Zoom Video Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) price target from $60 to $70. Wells Fargo analyst Michael Turrin maintained an Underweight rating. Zoom Video shares closed at $89.03 on Monday. <a href="https://www.benzinga.com/quote/ZM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler raised Health Catalyst, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCAT#NASDAQ">HCAT</a>) price target from $11 to $12. Piper Sandler analyst Jessica Tassan reiterated an Overweight rating. Health Catalyst shares closed at $8.52 on Monday.  <a href="https://www.benzinga.com/quote/HCAT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc boosted GitLab Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>) price target from $62 to $74. Keybanc analyst Jason Celino maintained an Overweight rating on the stock. GitLab shares closed at $66.37 on Monday. See how other analysts view this stock.</li>
<li>Deutsche Bank cut the price target for Hubbell Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBB#NYSE">HUBB</a>) from $493 to $473. Deutsche Bank analyst Nicole Deblase downgraded the stock from Buy to Hold. Hubbell shares settled at $463.86 on Monday. <a href="https://www.benzinga.com/quote/HUBB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HSBC boosted Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) price target from $128 to $131. HSBC analyst Saul Martinez downgraded the stock from Buy to Hold. Morgan Stanley shares closed at $133.66 on Monday. <a href="https://www.benzinga.com/quote/MS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo increased the price target for Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) from $100 to $115. Wells Fargo analyst Zachary Fadem maintained an Overweight rating. Starbucks shares closed at $101.84 on Monday. <a href="https://www.benzinga.com/quote/SBUX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler boosted The Allstate Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>) price target from $206 to $244. Piper Sandler analyst Paul Newsome maintained an Overweight rating. Allstate shares closed at $202.03 on Monday. <a href="https://www.benzinga.com/quote/ALL/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying SBUX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="583" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26090422/image-281-1024x583.png" alt="" class="wp-image-665498" style="width:659px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26090422/image-281-1024x583.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26090422/image-281-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26090422/image-281-768x437.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26090422/image-281.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42188912/jim-cramer-linde-is-a-terrific-company-sees-another-stock-up-75-as-not-done">Jim Cramer: Linde Is A &#8216;Terrific&#8217; Company, Sees Another Stock Up 75% As &#8216;Not Done&#8217;</a></li>
</ul>

Pre-Market Outlook

GTLB

HCAT

HUBB

SBUX

SMTC

Starbucks To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Tuesday

Barclays analyst Matt Miksic maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Overweight and raises the price target from $105 to $109.

Barclays Maintains Overweight on Medtronic, Raises Price Target to $109

<a href="https://www.medtronic.com/en-us/index.html">Medtronic plc</a>, a global leader in health care technology, announced today that the U.S. Department of Veterans Affairs (VA) has awarded a three-year Indefinite Delivery Indefinite Quantity (IDIQ) contract for <a href="https://www.medtronic.com/en-us/healthcare-professionals/products/digestive-gastrointestinal/gastrointestinal-artificial-intelligence/gi-genius-intelligent-endoscopy-module.html">GI Genius</a>&#x2122; AI-powered endoscopy units, resulting in almost 100 additional units being installed across VA medical centers nationwide. This expansion underscores the ability of Medtronic's proven technology to deliver state-of-the-art care to veterans, aiming to provide gold-standard diagnostic accuracy in colorectal screenings for thousands who served.

Contracts

Medtronic Awarded 3-Year VA Contract To Expand GI Genius AI Technology To Enhance Colorectal Cancer Detection In Veterans

Medtronic's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) short percent of float has fallen 4.76% since its last report. The company recently reported that it has 10.18 million shares sold short, which is 0.8% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.93 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Medtronic Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732302924_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Medtronic has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Medtronic's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Medtronic's peer group average for short interest as a percentage of float is 4.17%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Bernstein analyst Lee Hambright maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Outperform and raises the price target from $96 to $97.

Bernstein Maintains Outperform on Medtronic, Raises Price Target to $97

Wells Fargo analyst Larry Biegelsen maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Overweight and lowers the price target from $106 to $98.

Wells Fargo Maintains Overweight on Medtronic, Lowers Price Target to $98

Abbott Laboratories: Strong Q4 Results And Bullish Outlook

The healthcare IT market is driving digital transformation by enhancing efficiency, addressing workforce shortages, and promoting personalized care, making it a promising investment sector. Therefore, strong healthcare IT stocks like Medtronic (MDT), Abbott Laboratories (ABT), and Embecta (EMBC) could be wise additions to your portfolio. Read more... Healthcare IT is booming as health organizations increasingly invest in digital platforms like patient portals and virtual visits to enhance convenience, affordability, and the overall consumer experience. Strategies such as personalized care, extended service hours, and virtual health are improving accessibility and attracting a broader consumer base.
With innovation in healthcare on the rise, investors might consider fundamentally strong healthcare IT stocks like Medtronic plc (<a href="https://stocknews.com/stock/MDT/">MDT</a>), Abbott Laboratories (<a href="https://stocknews.com/stock/ABT/">ABT</a>), and Embecta Corp. (<a href="https://stocknews.com/stock/EMBC/">EMBC</a>).
Digital transformation revolutionizes healthcare by improving efficiency, addressing workforce shortages, and alleviating margin pressures. Investments in connected devices and AI-driven tools empower consumers to take control of their health, enhancing patient-clinician interactions. Hence, the healthcare IT market is projected to reach $592.49 billion by 2025, growing at an impressive <a href="https://www.thebusinessresearchcompany.com/report/healthcare-technology-global-market-report#:~:text=Healthcare%20Technology%20Market%20Size%202025,(CAGR)%20of%2016.8%25.">CAGR of 16.8%</a>.
Moreover, the healthcare sector is increasingly focusing on multidimensional strategies, such as organic growth and consumer retention, rather than relying solely on mergers and acquisitions. Tailored IT solutions, including user-friendly, cost-effective devices that deliver accurate and reliable results, bridge gaps in healthcare and drive growth.
Likewise, this year, the medical devices market is expected to reach an impressive revenue of <a href="https://www.statista.com/outlook/hmo/medical-technology/medical-devices/worldwide#analyst-opinion">$539.10 billion</a>. Considering these conducive trends, let's analyze the fundamentals of the three <a href="https://stocknews.com/category/medical-devices-equipment/">Medical - Devices &amp; Equipment</a> picks mentioned above, beginning with the third choice.
Stock #3: Medtronic plc (<a href="https://stocknews.com/stock/MDT/">MDT</a>)
Headquartered in Dublin, Ireland, Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and The Diabetes Operating Unit segment.
On January 13, 2025, MDT announced that the Centers for Medicare &amp; Medicaid Services (CMS) initiated a national coverage analysis for the Symplicity Spyral Renal Denervation System, a minimally invasive treatment for hypertension. This milestone reflects the growing public health need and robust data supporting the system's effectiveness in reducing blood pressure.
On the same date, MDT announced CE Mark approval for BrainSense Adaptive deep brain stimulation (aDBS) and Electrode Identifier in Europe and the UK. This technology offers real-time, personalized therapy for Parkinson's disease, marking a significant advancement in adaptive DBS systems.
In terms of the trailing-12-month <a href="https://www.investopedia.com/terms/l/levered-free-cash-flow.asp">levered FCF</a> margin, MDT's 15.19% is 530.7% higher than the 2.41% industry average. Its 27.77% trailing-12-month EBITDA margin is 385.1% higher than the 5.72% industry average. Similarly, the stock's 19.77% trailing-12-month EBIT margin is 731.8% higher than the 2.38% industry average.
MDT's net sales for the second quarter ended October 25, 2024, increased 5.2% from the prior-year period to $8.40 billion. The company's non-GAAP operating profit grew 1.6% over the prior-year quarter to $2.04 billion. Additionally, its non-GAAP net income was $1.62 billion, or $1.26 per share, indicating a marginal increase from the prior-year quarter.
For the quarter ending January 31, 2025, MDT's revenue is expected to increase 2.9% year-over-year to $8.33 billion. Its EPS for the same quarter is expected to grow 4.6% year-over-year to $1.36. It surpassed the consensus EPS estimates in each of the trailing four quarters. Over the past six months, the stock has gained 12.4% to close the last trading session at $89.25.
MDT's positive outlook is reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. It has an overall rating of B, equating to a Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
MDT has a B grade for Value and Stability. It is ranked #27 out of 131 stocks in the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical - Devices &amp; Equipment</a> industry. <a href="https://stocknews.com/stock/MDT/">Click here</a> to access additional ratings of MDT for Growth, Momentum, Sentiment, and Quality.
Stock #2: Abbott Laboratories (<a href="https://stocknews.com/stock/ABT/">ABT</a>)
ABT and its subsidiaries discover, develop, manufacture, and sell healthcare products worldwide. They operate in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
On December 17, 2024, ABT announced the world's first in-human leadless left bundle branch area pacing (LBBAP) procedures using its investigational AVEIR CSP leadless pacemaker system. This innovation combines conduction systems and leadless pacing technologies, offering a new treatment option for patients with slow heart rhythms.
On November 25, 2024, ABT announced the first patient procedures with its investigational balloon-expandable TAVI system for severe aortic stenosis. This system aims to lay the groundwork for AI-guided procedures, enhancing precision and expanding treatment options alongside ABT's Navitor TAVI system.
In terms of the trailing-12-month Capex / Sales, ABT's 5.34% is 69.6% higher than the 3.15% industry average. Its 15.54% trailing-12-month levered FCF margin is 545.3% higher than the 2.41% industry average. Also, its 16.82% trailing-12-month EBIT margin is 607.6% higher than the 2.38% industry average.
For the twelve months ended December 31, 2024, ABT's net sales rose 4.6% year-over-year to $41.95 billion. Its operating earnings increased 5.4% from the prior year to $6.83 billion. Additionally, the company's adjusted net earnings were $8.20 billion, or $4.67 per share, representing year-over-year increases of 5.1% and 5.2%, respectively.
Street expects ABT's EPS and revenue for fiscal 2029 to increase 15.1% and 8.2% year-over-year to $7.60 and $58.49 billion, respectively. It surpassed Street EPS and revenue estimates in three of the trailing four quarters. Over the past six months, the stock has gained 18.6% to close the last trading session at $123.22.
ABT's robust fundamentals are reflected in its POWR Ratings. It has an overall rating of B, which translates to a Buy in our proprietary rating system.
It has an A grade for Stability and a B for Quality. Within the same industry, it is ranked #13. To see ABT's Growth, Value, Momentum, and Sentiment ratings, <a href="https://stocknews.com/stock/ABT/">click here</a>.
Stock #1: Embecta Corp. (<a href="https://stocknews.com/stock/EMBC/">EMBC</a>)
EMBC is a medical device company that focuses on providing various solutions to enhance the health and well-being of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people in managing diabetes.
In terms of the trailing-12-month asset turnover ratio, EMBC's 0.90x is 116.2% higher than the 0.42x industry average. Likewise, its 65.46% trailing-12-month gross profit margin is 12.5% higher than the 58.2% industry average. Moreover, its 7.55% trailing-12-month EBITDA margin is 31.9% higher than the 5.72% industry average.
During the fiscal fourth quarter ended September 30, 2024, EMBC's revenues grew 1.5% year-over-year to $286.10 million, while its adjusted EBITDA for the quarter was $73 million. For the same period, the company's adjusted net income and adjusted net income per share were $25.90 million and $0.45, respectively.
Analysts expect EMBC's EPS for the quarter ending March 31, 2025, to increase 6.7% year-over-year to $0.72. Its revenue for the quarter ending June 30, 2025, is expected to rise 3.9% year-over-year to $283.21 million. EMBC surpassed the consensus EPS estimates in each of the trailing four quarters. Over the past nine months, the stock has gained 75.8% to close the last trading session at $19.13.
EMBC's POWR Ratings reflect strong prospects. It has an overall rating of A, translating to a Strong Buy in our proprietary system.
It is ranked first in the Medical - Devices &amp; Equipment industry. It has an A grade for Value and Quality and a B for Growth and Sentiment. <a href="https://stocknews.com/stock/EMBC/">Click here</a> to see EMBC's ratings for Momentum and Stability.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
ABT shares were trading at $124.77 per share on Friday afternoon, up $1.55 (+1.26%). Year-to-date, ABT has gained 10.89%, versus a 3.61% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Abhishek Bhuyan</h2> <img src='https:/wp-content/uploads/2023/07/ABhuyan.jpg' style="float:left; padding:5px;width:125px;">Abhishek embarked on his professional journey as a financial journalist due to his keen interest in discerning the fundamental factors that influence the future performance of financial instruments.<a href="https://stocknews.com/authors/?author=abhishek-bhuyan">More...</a>The post <a href=https://stocknews.com/news/abt-mdt-embc-3-healthcare-it-stocks-driving-digital-transformation/>3 Healthcare IT Stocks Driving Digital Transformation</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Healthcare IT Stocks Driving Digital Transformation

The automation industry is revolutionizing how businesses operate, with cutting-edge technologies driving efficiency, precision, and cost savings across sectors. As automation continues to reshape industries, fundamentally sound stocks like RTX Corporation (RTX), Medtronic (MDT), and Parker-Hannifin (PH) are poised to benefit from this growth. Read on… The automation industry is transforming businesses' operations, creating smarter, more efficient systems across multiple sectors like manufacturing, healthcare, and logistics. In an era where cost reduction and streamlined workflows are paramount, industries are increasingly adopting automated solutions to stay competitive and meet growing demands.
As the automation landscape continues to evolve, some companies like RTX Corporation (<a href="https://stocknews.com/stock/RTX/">RTX</a>), Medtronic plc (<a href="https://stocknews.com/stock/MDT/">MDT</a>), and Parker-Hannifin Corporation (<a href="https://stocknews.com/stock/PH/">PH</a>) are leading the charge and are well-positioned to capitalize on the industry's tailwinds.
By now, we know that the potential for growth in AI and automation is enormous. McKinsey estimates that AI technologies could inject<a href="https://www.mckinsey.com/industries/metals-and-mining/our-insights/ai-the-next-frontier-of-performance-in-industrial-processing-plants"> up to $13 trillion</a> into the global economy by 2030. Whether it's self-driving cars, robotic arms revolutionizing manufacturing, or AI algorithms enabling better decision-making in finance and healthcare, the applications of automation seem boundless. The automation market is forecast to reach $238.01 billion by 2030, growing at a <a href="https://www.industryarc.com/Report/15493/automation-market.html">CAGR of 7.2%</a>.
Moreover, the machine tools market, valued at <a href="https://www.grandviewresearch.com/industry-analysis/machine-tools-market">$97.93 billion in 2024</a>, is projected to grow at a CAGR of 7% through 2030. This growth is driven by innovations like multi-axis robotics and smarter manufacturing techniques that prioritize precision and minimize downtime. As industries continue to embrace these technologies, automation is becoming an indispensable part of the global economy.
Let's dig deeper into the fundamental aspects of the aforementioned stocks in detail:
RTX Corporation (<a href="https://stocknews.com/stock/RTX/">RTX</a>)
RTX is a global provider of systems and services for commercial, armed forces, and governmental clients in the aerospace and defense industries. It operates through three segments: Collins Aerospace; Pratt &amp; Whitney; and Raytheon.
On January 16, RTX secured a $529 million contract to supply the Netherlands with a Patriot air and missile defense system fire unit, replacing one previously donated to Ukraine. This was followed by a $333 million contract awarded on January 13 by the U.S. Navy for producing Standard Missile-6 (SM-6) Block IA missiles.
These contracts underscore RTX's expertise in missile defense systems and its critical role in strengthening national and allied defense capabilities while substantially boosting its revenue streams.
On December 12, 2024, the company paid its shareholders a quarterly dividend of $0.63 per share. RTX pays an annual dividend of $2.52, which translates to a dividend yield of 2.08% at the prevailing price levels. Its four-year average dividend yield is 2.34%. Moreover, its dividend payouts have increased at a CAGR of 7.3% over the past three years.
RTX's trailing 12-month EBITDA margin of 15.90% is 13.8% higher than the industry average of 13.98%. Likewise, its trailing 12-month levered FCF margin of 10.21% is 48.5% higher than the industry average of 6.88%.
During the fiscal third quarter that ended September 30, 2024, RTX's sales increased 49.2% year-over-year to $20.09 billion. Its adjusted operating profit grew 11.3% from the year-ago value to $2.48 billion. Its adjusted net income attributable to common shareowners amounted to $1.47 billion, reflecting an increase of 6.9% from the prior-year quarter. In addition, the company's adjusted EPS came in at $ 1.45, up 16% year-over-year.
Analysts expect RTX's <a href="https://www.investopedia.com/terms/e/eps.asp">EPS</a> and revenue for the fourth quarter ended December 31, 2024, to increase 6.6% and 3.1% year-over-year to $1.38 and $ 20.54 billion, respectively. Moreover, it surpassed the consensus EPS and revenue estimates in each of the trailing four quarters, which is promising.
Over the past year, the stock has gained 42.4% to close the last trading session at $121.11. Also, it has gained 15.4% over the past six months.
RTX's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect this robust outlook. The stock has an overall rating of B, equating to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 distinct factors, with each factor weighted to an optimal degree.
RTX has an A grade for Momentum and a B for Growth. It is ranked #9 out of 70 stocks in the <a href="https://stocknews.com/category/air-defense/">Air/Defense Services</a> industry.
Beyond what we have stated above, we have also given RTX grades for Value, Stability, Sentiment, and Quality. You can get all the RTX ratings <a href="https://stocknews.com/stock/RTX/">here</a>.
Medtronic plc (<a href="https://stocknews.com/stock/MDT/">MDT</a>)
Headquartered in Dublin, Ireland, MDT provides healthcare technology solutions. It develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The company operates through four segments: Cardiovascular Portfolio; Neuroscience Portfolio; Medical Surgical Portfolio; and Diabetes Operating Unit.
On January 13, 2025, MDT announced that the Centers for Medicare &amp; Medicaid Services (CMS) had initiated a national coverage analysis for renal denervation, aiming to develop Medicare coverage policy for hypertension treatments. This move supports MDT's Symplicity Spyral RDN system, potentially increasing patient access and strengthening the company's position in the healthcare technology market.
In the same month, buoyed by its strong financial performance, the company paid a dividend of $0.70 per share for the third quarter of fiscal year 2025. It pays an annual dividend of $2.80, which translates to a dividend yield of 3.21% at the prevailing price levels. Its four-year average dividend yield is 2.85%. Moreover, its dividend payouts have increased at a CAGR of 4.1% over the past three years.
The stock's trailing 12-month gross profit margin of 65.40% is 12% higher than the industry average of 58.37%. Likewise, its trailing-12-month EBIT and levered FCF margins of 19.77% and 15.19% are considerably above their respective industry averages of 2.68% and 2.33%.
MDT's revenue increased 5.2% year-over-year to $8.40 billion in the fiscal 2025 second quarter that ended on October 25, 2024. Its non-GAAP operating profit came in at $ 2.04 million, up 1.6% year-over-year. In addition, the company's non-GAAP net income reached $ 1.62 billion or $ 1.26 per share, indicating a marginal increase from the prior year quarter.
The consensus revenue estimate of $8.33 billion for the third quarter (ending January 2025) represents a 2.9% improvement year over year. The consensus EPS estimate of $1.36 for the same period indicates a 4.6% increase from the previous year. The company has an impressive surprise history, surpassing the consensus revenue and EPS estimates in each of the trailing four quarters.
The stock has surged 8.4% over the past six months and 10.3% year-to-date to close the last trading session at $88.08.
MDT's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of B, which equates to Buy in our proprietary rating system.
It has a B grade for Value and Stability. Of the 133 stocks in the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical - Devices &amp; Equipment</a>, it is ranked #23. To access MDT's Growth, Momentum, Sentiment, and Quality ratings, <a href="https://stocknews.com/stock/MDT/">click here</a>.
Parker-Hannifin Corporation (<a href="https://stocknews.com/stock/PH/">PH</a>)
PH specializes in motion and control technologies, serving industrial, mobile, and aerospace markets through its Diversified Industrial and Aerospace Systems segments. It offers a wide range of products, including motion-control systems, sealing solutions, filtration, and aerospace components, distributed via OEMs and sales networks worldwide.
On November 4, 2024, PH announced the completion of its divestiture of the North America Composites and Fuel Containment (CFC) Division to SK Capital Partners. This move aligns with the company's strategic focus on core business areas in motion and control technologies.
The stock's trailing-12-month net income margin of 14.47% is 122.6% higher than the industry average of 6.50%. Likewise, its trailing-12-month EBIT and levered FCF margins of 20.25% and 12.38% are 95.9% and 80% above their respective industry average of 10.33% and 6.88%.
PH's net sales increased 1.2% year-over-year to $4.90 billion in the fiscal 2025 first quarter that ended on September 30, 2024. Its income before income taxes grew 6.7% from the year-ago value to $ 875.19 million. The company's adjusted net income attributable to common shareholders came in at $809.79 million, up 4.3% year-over-year, while adjusted EPS rose 4% from the prior year's quarter to $6.20.
Street expects PH's EPS for the fiscal second quarter (ended December 31, 2024) to increase 1.3% year-over-year to $6.23, while its revenue for the same period is expected to be $4.80 billion. In addition, it surpassed the consensus EPS and revenue estimates in each of the trailing four quarters.
Shares of PH have gained 46.8% over the past year and 20% over the past six months to close the last trading session at $669.46.
PH's strong fundamentals are reflected in its POWR Ratings. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
It has a B grade for Momentum, Stability, and Quality. Within the <a href="https://stocknews.com/category/industrial-equipment/">Industrial – Equipment</a> industry, it is ranked #24 out of 89 stocks. <a href="https://stocknews.com/stock/PH/">Click here</a> to see PH's ratings for Growth, Value, and Sentiment.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
RTX shares closed at $121.11 on Friday, up $0.65 (+0.54%). Year-to-date, RTX has gained 4.66%, versus a 1.96% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/rtx-mdt-ph-3-stocks-leading-the-automation-revolution/>3 Stocks Leading the Automation Revolution</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Stocks Leading the Automation Revolution

Stryker: A Cool Name For An Awesome Company, But Is It A Buy Ahead Of Earnings?

Beta Bionics sets terms for upsized $165M IPO

Franklin Mutual Beacon Fund Q4 2024 Commentary

BBNX

DBSDF

DBSDY

EMBC

FERG

HEINY

HINKF

HLNCF

ISRG

NOBL

PODD

RBGLY

RBGPF

SPGI

SSNLF

TNDM

Screenshot 2024-10-03 at 5.30.47 PM

Health Care

DXCM

GCTK

SENS

Expanding Continuous Glucose Monitoring Options: How Glucotrack Is Helping Usher In The Next Generation Of Diabetes Care Technology

Screenshot 2024-09-30 at 5.38.54 PM

Movers & Shakers

COSM

Nestle Sponsored representing Registered Shares Series B

NSRGY

VTRS

How Cosmos Health&#39;s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

Press Releases

"Market Movers: CTOR, CTNT, PNPN.V, KITT, SHIM – More Stocks Inside to Watch"

Small Cap

Opinion

The Intersection of AI, Medicine, and Stocks: A New Era of Opportunities Issued on behalf of Avant Technologies Inc.

Dividends

Medtronic announces cash dividend for third quarter of fiscal year 2025

"Cardiol Therapeutics (NASDAQ: CRDL) Heart Health Innovation – AVCO, GXAI, UPC, and More Stocks Driving Groundbreaking Advances"

Why Healthcare Providers Are Increasingly Trusting Artificial Intelligence for Detection & Diagnosis

Medtronic Chairman and CEO Geoff Martha to speak at J.P. Morgan healthcare conference

Medtronic achieves CE Mark approval for BrainSense™ Adaptive deep brain stimulation and Electrode Identifier, a groundbreaking advance in personalized, sensing-enabled care for people with Parkinson's through innovative brain-computer interface technology

Medtronic announces CMS national coverage analysis for Symplicity™ Spyral Renal Denervation System

How HealthCare Industry is Leveraging Artificial Intelligence to Revolutionize Diagnostics and Early Disease Detection

Comments

Medtronic

ニュース

最新ニュース Medtronic (NYSE:MDT) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル